首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Signal transduction and targeted therapy

缩写:

ISSN:2095-9907

e-ISSN:2059-3635

IF/分区:52.7/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引2606
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Xiujian Wang,Xiao Tao,Pengjie Chen et al. Xiujian Wang et al.
Clinical evidence supports the notion that T cell exhaustion and terminal differentiation pose challenges to the persistence and effectiveness of chimeric antigen receptor-T (CAR-T) cells. MEK1/2 inhibitors (MEKIs), widely used in cancer tr...
Liping Dou,Yanli Zhao,Jingjing Yang et al. Liping Dou et al.
Newly diagnosed patients with high-risk acute graft-versus-host disease (aGVHD) often experience poor clinical outcomes and low complete remission rates. Ruxolitinib with corticosteroids showed promising efficacy in improving response and f...
Sai-Wei Huang,Wei Jiang,Sha Xu et al. Sai-Wei Huang et al.
The identification of predictors for immunotherapy is often hampered by the absence of control groups in many studies, making it difficult to distinguish between prognostic and predictive biomarkers. This study presents biomarker analyses f...
Ran Liu,Zixuan Luo,Chong Dai et al. Ran Liu et al.
Granulomatous lobular mastitis (GLM) is a chronic idiopathic granulomatous mastitis of the mammary gland characterized by significant pain and a high propensity for recurrence, the incidence rate has gradually increased, and has become a se...
Bo Wu,Bo Zhang,Bowen Li et al. Bo Wu et al.
Immunotherapy has made significant strides in cancer treatment, particularly through immune checkpoint blockade (ICB), which has shown notable clinical benefits across various tumor types. Despite the transformative impact of ICB treatment ...
Liuqing Yang,Ye Yang,Jing Zhang et al. Liuqing Yang et al.
PROteolysis TArgeting Chimeras (PROTACs) have been considered the next blockbuster therapies. However, due to their inherent limitations, the efficacy of PROTACs is frequently impaired by limited tissue penetration and particularly insuffic...